Literature DB >> 2250107

IgG subclasses in the serum and skin in subacute cutaneous lupus erythematosus and neonatal lupus erythematosus.

S D Bennion1, C Ferris, T S Lieu, C B Reimer, L A Lee.   

Abstract

IgG subclasses differ in their biologic and chemical properties, such as complement fixation, protein and cellular binding, and placental transfer. In this study, IgG subclasses of anti-Ro/SSA antibodies in subacute cutaneous lupus (SCLE) and neonatal lupus (NLE) are examined in the serum and in the skin. IgG subclasses in NLE beginning in utero (NLE-heart disease) are compared to subclasses in NLE beginning after birth (NLE-skin disease). Human skin was grafted onto athymic mice, mice were injected with one of eight anti-Ro/SSA maternal NLE sera (four heart block, four skin disease) or seven anti-Ro/SSA SCLE sera, and grafts were examined for IgG subclasses using monoclonal anti-human IgG subclass reagents in an immunofluorescent technique. Lesional skin was examined from four SCLE patients. IgG1 was the only IgG subclass detected in the grafts and skin lesions. IgG1 was the predominant anti-Ro/SSA IgG subclass detected in SCLE and NLE sera in an ELISA using a synthetic Ro/SSA polypeptide. These studies show that the maternal anti-Ro/SSA autoantibodies in NLE-heart disease sera are predominantly IgG1 and are therefore likely to be present in the fetus at the time of gestation, when heart block usually develops. Second, differences in the clinical presentations of NLE (in utero vs. postnatal disease) cannot be attributed to differences in anti-Ro/SSA IgG subclasses. Finally, the subclass bound in the skin in SCLE is IgG1, a subclass capable of mediating tissue injury via complement or cellular effectors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2250107     DOI: 10.1111/1523-1747.ep12514311

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases.

Authors:  J G Routsias; A G Tzioufas; M Sakarellos-Daitsiotis; C Sakarellos; H M Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

Review 2.  Neonatal lupus: clinical features and management.

Authors:  Lela A Lee
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 3.  Pathophysiology of cutaneous lupus erythematosus.

Authors:  Julie H Lin; Jan P Dutz; Richard D Sontheimer; Victoria P Werth
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 10.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.